Related MeSH Hierarchy (8)
Diseases [C] » Infections [C01] » Communicable Diseases » Blood-Borne Infections » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Infections [C01] » Communicable Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Infections [C01] » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Retroviridae Infections » Lentivirus Infections » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Infections [C01] » Virus Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Infections [C01] » Virus Diseases » Slow Virus Diseases » Acquired Immunodeficiency Syndrome
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections » Acquired Immunodeficiency Syndrome
Diseases [C] » Immune System Diseases [C20] » Immunologic Deficiency Syndromes » HIV Infections » Acquired Immunodeficiency Syndrome
Description
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. MeSH
Hierarchy View
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (40)
Phase 3 Indicated Drugs (17)
Phase 2 Indicated Drugs (24)
Phase 1 Indicated Drugs (17)
Other Experimental Indicated Drugs (15)
Organization Involved with Phase 4 Indications (127)
Badalona Hospital Germans Trias i Pujol
Bill and Melinda Gates Foundation
California HIV/AIDS Research Program
Canadian AIDS Treatment Information Exchange
Catholic University of Sacred Heart, Rome
Centers for Disease Control and Prevention (CDC)
Community Research Initiative of New England
Drugs for Neglected Diseases Initiative
Federal University of Rio de Janeiro
Guangdong Provincial Maternal and Child Health Hospital
HIV-NAT Thai Red Cross AIDS Research Center
Hospital Universitario Ramon y Cajal
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de Enfermedades Respiratorias
Instituto Nacional de la Nutrición Salvador Zubiran
Joint Clinical Research Centre, Kampala, Uganda
Laboratorios Nacionales de Biológicos y Reactrivos
Mater Misericordiae University Hospital
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
National University of Ireland
NHS Health Technology Assessment Programme
Puerto Rico Community Network for Clinical Research on AIDS
St. Vincent's Hospital-Manhattan
Taipei Veteran General hospital
The American Society of Tropical Medicine and Hygiene
The HIV Netherlands Australia Thailand Research Collaboration
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Université catholique de Louvain
University of British Columbia
University of California, Davis
University of California, Riverside
University of California, San Francisco
University of Illinois at Chicago
University of North Carolina at Chapel Hill
University of Southern California
Organization Involved with Phase 3 Indications (105)
AIDS Community Research Initiative of America
All India Institute of Medical Sciences
Canadian Institutes of Health Research (CIHR)
Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS
Chelsea and Westminster Hospital NHS Foundation Trust
Chiangrai Prachanukroh Hospital
CIHR Canadian HIV Trials Network
Comprehensive International Program of Research on AIDS
European and Developing Countries Clinical Trials Partnership (EDCTP)
Follow-on African Consortium for Tenofovir Studies
French National Agency for Research on AIDS and Viral Hepatitis
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Icahn School of Medicine at Mount Sinai
Indian Council of Medical Research
Infectious Disease Institute, Kampala, Uganda
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Institute for Human Genetics and Biochemistry
Luigi Sacco University Hospital
National Cancer Institute (NCI)
National Center for HIV/AIDS, Dermatology, and STDs, Phnom Penh, Cambodia
National Institute for Research in Tuberculosis, Chennai, India
National Institute of Mental Health (NIMH)
New York Presbyterian Hospital
Perinatal HIV Research Unit, Baragwanath
RojanPharma Pharmaceutical Company
South East Asia Research Collaboration with Hawaii
St. Petersburg City Health Department
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Organization Involved with Phase 2 Indications (116)
AmpliPhi Biosciences Corporation
Armauer Hansen Research Institute, Ethiopia
Autonomous University of Madrid
California Family Health Council
California Institute for Medical Research
Canadian Foundation for AIDS Research (CANFAR)
Case Western Reserve University
Centre for Infectious Disease Research in Zambia (CIDRZ)
Evangelisches Studienwerk Villigst
Frontier Biotechnologies Co., Ltd.
Georg Friedrich Rexroth Stiftung, Lohr, Germany
German Leprosy and Tuberculosis Relief Association
Hektoen Institute for Medical Research
Hoosier Cancer Research Network
Institut d'Investigacions Biomèdiques August Pi i Sunyer
International AIDS Vaccine Initiative
International Partnership for Microbicides
International Partnership for Microbicides, Inc.
Medical Research Council-UVRI Uganda Research Unit on AIDS
Medical University of Southern Africa
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Institute of Cancerología
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Neurological Disorders and Stroke (NINDS)
Nebraska Centre for Substance Abuse Research
People's Liberation Army of China
Organization Involved with Phase 1 Indications (52)
AIDS Research Consortium of Atlanta
Centers for Disease Control and Prevention, China
Henry M. Jackson Foundation for the Advancement of Military Medicine
National Human Genome Research Institute (NHGRI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Oak Crest Institute of Science
Ragon Institute of MGH, MIT and Harvard
Organization Involved with Other Experimental Indications (43)
Cantonal Hospital of St. Gallen
Catholic University of Health and Allied Sciences
Centers for Medicare and Medicaid Services
Danish Council for Development Research
Federal University of Rio Grande do Sul
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
